The Exchange has sought clarification from Sakar Healthcare Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013 or as per Indian Accounting Standard The response of the Company is awaited.
SAKAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The NSE has asked Sakar Healthcare to clarify why its financial results for the quarter ended 30 September 2025 were not submitted in the format prescribed under Schedule III of the Companies Act, 2013, or as per Indian Accounting Standards. This falls under Regulation 33 of SEBI's Listing Obligations and Disclosure Requirements. The company's response is still awaited. No penalty or further action has been announced at this stage. Shareholders will need to wait for the company's reply and any follow-up from the exchange.
This is currently a routine compliance query from the exchange regarding the format of reported numbers, not a penalty or enforcement action. If the company fails to respond satisfactorily or the issue escalates, it could draw regulatory scrutiny and affect stock sentiment, but no immediate material impact is indicated.